GSK Plc Valuation
GLAXF Stock | USD 16.90 1.11 7.03% |
At this time, the firm appears to be overvalued. GSK plc retains a regular Real Value of $14.86 per share. The prevalent price of the firm is $16.9. Our model calculates the value of GSK plc from analyzing the firm fundamentals such as Operating Margin of 0.25 %, return on asset of 0.0659, and Return On Equity of 0.31 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that GSK Plc's price fluctuation is not too volatile at this time. Calculation of the real value of GSK plc is based on 3 months time horizon. Increasing GSK Plc's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the GSK pink sheet is determined by what a typical buyer is willing to pay for full or partial control of GSK plc. Since GSK Plc is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GSK Pink Sheet. However, GSK Plc's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 16.9 | Real 14.86 | Hype 16.9 |
The real value of GSK Pink Sheet, also known as its intrinsic value, is the underlying worth of GSK plc Company, which is reflected in its stock price. It is based on GSK Plc's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of GSK Plc's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of GSK plc helps investors to forecast how GSK pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GSK Plc more accurately as focusing exclusively on GSK Plc's fundamentals will not take into account other important factors: GSK Plc Total Value Analysis
GSK plc is currently anticipated to have takeover price of 90.86 B with market capitalization of 73.5 B, debt of 19.76 B, and cash on hands of 6.53 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the GSK Plc fundamentals before making investing decisions based on enterprise value of the companyTakeover Price | Market Cap | Debt Obligations | Cash |
90.86 B | 73.5 B | 19.76 B | 6.53 B |
GSK Plc Investor Information
About 41.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.11. GSK plc last dividend was issued on the 23rd of February 2023. The entity had 4:5 split on the 19th of July 2022. Based on the measurements of operating efficiency obtained from GSK Plc's historical financial statements, GSK plc is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.GSK Plc Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. GSK Plc has an asset utilization ratio of 48.75 percent. This implies that the Company is making $0.49 for each dollar of assets. An increasing asset utilization means that GSK plc is more efficient with each dollar of assets it utilizes for everyday operations.GSK Plc Ownership Allocation
GSK plc has a total of 4.09 Billion outstanding shares. 30% of GSK plc outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Therefore, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.GSK Plc Profitability Analysis
The company reported the revenue of 29.32 B. Net Income was 14.96 B with profit before overhead, payroll, taxes, and interest of 19.92 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates GSK Plc's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in GSK Plc and how it compares across the competition.
About GSK Plc Valuation
The pink sheet valuation mechanism determines GSK Plc's current worth on a weekly basis. Our valuation model uses a comparative analysis of GSK Plc. We calculate exposure to GSK Plc's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GSK Plc's related companies.GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Glaxosmithkline Plc is traded on OTC Exchange in the United States.
8 Steps to conduct GSK Plc's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates GSK Plc's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct GSK Plc's valuation analysis, follow these 8 steps:- Gather financial information: Obtain GSK Plc's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine GSK Plc's revenue streams: Identify GSK Plc's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research GSK Plc's industry and market trends, including the size of the market, growth rate, and competition.
- Establish GSK Plc's growth potential: Evaluate GSK Plc's management, business model, and growth potential.
- Determine GSK Plc's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate GSK Plc's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
GSK Plc Growth Indicators
Investing in growth stocks can be very risky. If the company such as GSK Plc does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding | 4.1 B | |
Quarterly Earnings Growth Y O Y | 0.97 | |
Forward Price Earnings | 9.7087 | |
Retained Earnings | 4.4 B |
Complementary Tools for GSK Pink Sheet analysis
When running GSK Plc's price analysis, check to measure GSK Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GSK Plc is operating at the current time. Most of GSK Plc's value examination focuses on studying past and present price action to predict the probability of GSK Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GSK Plc's price. Additionally, you may evaluate how the addition of GSK Plc to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |